Sekar Kathiresan (Verve)
January 19, 2021 07:26 AM ESTUpdated 09:22 AM
Financing
Cell/Gene Tx

'Bluest of blue-chip in­vestors' pump $94M in­to Sekar Kathire­san's quest to bring CRISPR to the heart

Amber Tong

Go­ing in­to his first JP Mor­gan con­fer­ence, Sekar Kathire­san had some ma­jor news to share. His am­bi­tious car­dio­vas­cu­lar-fo­cused start­up, Verve Ther­a­peu­tics, had des­ig­nat­ed the PC­SK9 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times